Female Contraception – Pipeline Review, H1 2016 Featuring Agile Therapeutics, ANI Pharmaceuticals, Evofem, Mithra Pharmaceuticals & Orbis Biosciences – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Female
Contraception – Pipeline Review, H1 2016″ drug pipelines to
their offering.

Female Contraception (birth control) prevents pregnancy by interfering
with the normal process of ovulation, fertilization, and implantation.
There are many contraceptive methods which include implants and
injections, intrauterine devices (IUDs), pills and vaginal rings,
barrier methods, sterilization and natural methods. Contraception
generally works by preventing sperm from reaching and fertilizing an egg
(barrier and IUD methods), preventing an egg from being released every
month (hormones), blocking the reproductive function (sterilization) and
preventing a fertilized egg from implanting in the uterus (hormones).

Female Contraception pipeline therapeutics constitutes close to 19
molecules. Out of which approximately 16 molecules are developed by
Companies and remaining by the Universities/Institutes. The molecules
developed by Companies in Pre-Registration, Phase III, Phase II, Phase
I, Preclinical and Discovery stages are 1, 3, 2, 1, 3 and 6
respectively. Similarly, the Universities portfolio in Phase III and
Preclinical stages comprises 1 and 2 molecules, respectively.

Female Contraception – Pipeline Review, H1 2016, outlays comprehensive
information on the therapeutics under development for Female
Contraception, complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type. It also reviews of key players involved in therapeutic
development for Female Contraception and features dormant and
discontinued projects.

Key Topics Covered:

1. Introduction
2. Female Contraception Overview
3. Therapeutics Development
4. Pipeline Products for Female Contraception – Overview
5. Pipeline Products for Female Contraception – Comparative Analysis
6. Female Contraception – Therapeutics under Development by Companies
7. Female Contraception – Therapeutics under Investigation by
   Universities/Institutes
8. Female Contraception Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Female Contraception – Products under Development by Companies
13. Female Contraception – Products under Investigation by
    Universities/Institutes
14. Female Contraception – Companies Involved in Therapeutics Development

• Agile Therapeutics, Inc.
• ANI Pharmaceuticals, Inc.
• Evofem, Inc.
• Mithra Pharmaceuticals S.A.
• Orbis Biosciences, Inc.

For more information visit http://www.researchandmarkets.com/research/4nh5jc/female

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women’s
Health